Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
Aim. To perform health-economic evaluation of trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer and CNS metastases. Materials and methods. Cost-effectiveness analysis along with sensitivity analysis and budget impact analysis were performed. Direct medical costs and indirect costs (...
| Asıl Yazarlar: | , , , , |
|---|---|
| Materyal Türü: | Makale |
| Dil: | Russian |
| Baskı/Yayın Bilgisi: |
Izdatelstvo OKI
2018-05-01
|
| Seri Bilgileri: | Качественная клиническая практика |
| Konular: | |
| Online Erişim: | https://www.clinvest.ru/jour/article/view/82 |